Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1017-1023

  Lopez Cortes, Luis F ^a   Ruiz Valderas, Rosa ^a   Ruiz Morales, Josefa ^b   Leon, Eva ^c   Vergara de Campos, Antonio ^c   Marin Niebla, Ana ^a   Marquez Solero, Manuel ^b   Lozano, Fernando ^c   Valiente, Rebeca ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

HIV infection; Pharmacokinetics; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; OXAZINE DERIVATIVE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLASSIFICATION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INTERACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; TUBERCULOSIS; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TUBERCULOSIS;

EID: 34249070708     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl357     Document Type: Article

References (34)

1. Godoy P, Castilla J, Rullan JV. Incidence and risk factors of the association of AIDS and tuberculosis in Spain. Med Clin (Barc) 1998; 110: 205-8.
2. Pulido F, Pena JM, Rubio R et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157: 227-32.
3. Girardi E, Palmieri F, Cingolani A et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 326-31.
4. Lopez-Cortes LF, Marin-Niebla A, Lopez-Cortes LE et al. Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients. Int J Tuberc Lung Dis 2005; 9: 1385-90.
5. Korenromp EL, Scano F, Williams BG et al. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampicin-based treatment: An analytical review. Clin Infect Dis 2003; 37: 101-12.
6. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
7. Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2004; 53 37.
8. Losso MH, Lourtau LD, Toibaro JJ et al. The use of saquinavir/ ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampicin. Antivir Ther 2004; 9: 1031-3.
9. Ribera E, Azuaje C, Lopez RM et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD study). J Acquir Immune Defic Syndr 2005; 40: 317-23.
10. Ribera E, Pou L, Lopez RM et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28: 450-3.
11. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681-90.
12. Pedral-Sampaio DB, Alves CR, Netto EM et al. Efficacy and safety of efavirenz in HIV patients on rifampicin for tuberculosis. Braz Infect Dis 2004; 8: 211-6.
13. Patel A, Patel K, Patel J et al. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004; 37 1166-9.
14. Brennan-Benson P, Lyus R, Harrison T et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: One size does not fit all. AIDS 2005; 19: 1541-3.
15. Manosuthi W, Kiertiburanakul S, Sungkanuparph S et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20: 131-2.
16. Dybul M, Nies-Kraske E, Dewar R et al. A proof-of-concept study short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 2004; 189: 1974-82.
17. Lopez-Cortes LF, Ruiz-Valderas R, Marin-Niebla A et al. Therapeutic drug monitoring of efavirenz: Trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr 2005; 39: 551-6.
18. Sarasa-Nacenta M, Lopez-Pua Y, Lopez-Cortes LF et al. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 2001; 763: 53-9.
19. Joshi AS, Barrett JS, Fiske WD et al. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy. In: Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1201. American Society for Microbiology, Washington, DC, USA.
20. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
21. Csajka C, Marzolini C, Fattinger K et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73 20-30.
22. Langmann P, Weissbrich B, Desch S et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur J Med Res 2002; 7: 309-14.
23. Stahle L, Moberg L, Svensson JO et al. Efavirenz plasma concentrations in HIV-infected patients: Inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004; 26: 267-70.
24. Brundage RC, Yong FH, Fenton T et al. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004; 48 979-84.
25. Ribaudo H, Clifford D, Gulick R et al. Relationships between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: Results from ACTG A5095/A5097s. In: Abstracts of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, 2004. Abstract 132. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
26. Dworkin MS, Adams MR, Cohn DL et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr 2005; 39: 464-7.
27. Wood E, Hogg RS, Yip B et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther 2004; 9: 229-35.
28. D'arminio Monforte A, Cozzi-Lepri A, Phillips A et al. Interruption highly active antiretroviral therapy in HIV clinical practice: Results from the Italian cohort of antiretroviral-naive patients. J Acquir Immune Defic Syndr 2005; 38: 407-16.
29. Clifford DB, Evans S, Yang Y et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143: 714-21.
30. Manosuthi W, Sungkanuparph S, Thakkinstian A et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19: 1481-6.
31. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group Study. AIDS 2004; 18: 2391-400.
32. Kappelhoff BS, Huitema AD, Yalvac Z et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44: 849-61.
33. Burger D, van der Heiden I, la Porte C et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61: 148-54.
34. Ribaudo HJ, Haas DW, Tierney C et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42: 401-7.